BBNX

New York, New York--(Newsfile Corp. - October 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.

SAN FRANCISCO, Oct. 16, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026. The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower.

Philadelphia, Pennsylvania--(Newsfile Corp. - October 16, 2026) - Berger Montague PC, a leading national plaintiffs' law firm, announces a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) ("Beta Bionics" or the "Company") on behalf of investors who purchased or acquired Beta Bionics securities during the period from July 30, 2025 through February 24, 2026 (the "Class Period"). The deadline to apply for lead plaintiff is November 3, 2026.

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Beta Bionics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.

New York, New York--(Newsfile Corp. - October 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

San Francisco, California--(Newsfile Corp. - October 15, 2026) - Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026. The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower.

NEW ORLEANS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company's common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

New York, New York--(Newsfile Corp. - October 15, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.